vinorelbine
Showing 1 - 4 of 4
HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine
Recruiting
- HER2-negative Breast Cancer
- +5 more
- Camrelizumab with vinorelbine and cisplatin
-
Beijing, Beijing, ChinaPeking University First Hospital
Oct 15, 2022
Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)
Completed
- Anaplastic Large Cell Lymphoma
- Vinorelbine
-
Shanghai, Shanghai, ChinaShanghai Children's Medical Center
Jul 23, 2022
Breast Cancer, Pyrotinib, Breast Diseases Trial in Guangzhou (Pyrotinib 320mg + Vinorelbine, Pyrotinib 400mg + Vinorelbine,
Recruiting
- Breast Cancer
- +4 more
- Pyrotinib 320mg + Vinorelbine
- +2 more
-
Guangzhou, ChinaZhang Jingmin
Apr 24, 2022
Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)
Recruiting
- Anaplastic Large Cell Lymphoma
- Vinorelbine
-
Shanghai, Shanghai, ChinaShanghai Children's Medical Center
Jul 28, 2021